Three significant studies of Ivermectin in Covid-19  have been released in the past week, with two sets of meta-analyses delivering contradictory results and the third  — a randomised, double-blind placebo trial —  finding no significant effect on hospitalisation, reported MedicalBrief (7 July 2021). In SA, the DoH's most recent evidence review remains firm that Ivermectin “does not suggest any clear benefits with respect to mortality, clinical improvement, or viral clearance”. The research includes a meta-analysis, published in the American Journal of Therapeutics, another meta-analysis, published in Clinical Infectious Diseases and the most recently published research BMC Clinical Diseases .

Other news